Clinical Study on the Application of Oncolytic Virus in Recurrent Glioblastoma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
This clinical trial aims to evaluate whether an oncolytic viral agent can treat recurrent glioblastoma. It will also assess the safety and tolerability of the oncolytic viral agent. The primary question it seeks to answer is: What medical problems do participants experience when injected with the oncolytic viral agent? Researchers will administer the oncolytic viral agent via intratumoral injection to determine its efficacy in treating recurrent glioblastoma.
Participant Procedures:
Receive the initial injection, followed by additional injections every 2-4 weeks for a total of 6 injections.
Undergo physical examinations and tests every 2 to 4 weeks. Record their symptoms, hematological test results, and imaging findings.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
oncolytic virus in recurrent glioblastoma
干预措施: oncolytic virus (Biological)
结局指标
主要结局
Maximum tolerated dose
时间窗: 4 hours, 2 days, 7 days and 14 days after administration
次要结局
未报告次要终点
研究者
Liangxue Zhou
Dr.
Mianyang Central Hospital